Communication from the Ministry of Health No. 118 / 2024 Coll.
Communication from the Ministry of Health on the antigenic composition of vaccines against pneumococcal infections for vaccination of insured persons over 65 years of age
Valid
Communication
118
COMMUNICATION
Ministry of Health
of 30 April 2024
on the antigenic composition of vaccines against pneumococcal infections for the vaccination of insured persons over 65 years of age
The Ministry of Health pursuant to § 30 (2) (f) of Act No. 48 / 1997 Coll., on Public Health Insurance and amending and supplementing certain related laws, as amended, provides for the antigenic composition of the vaccine against pneumococcal infections for vaccination of insured persons over 65 years of age:
1) A 20-valent polysaccharide conjugate vaccine against pneumococcal infections, which contains:
Polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 1 1,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 31,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 41,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 51,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 6A1,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 6B1,2 4,4 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 7F1,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 81,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 9V1,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 10A1,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 11A1,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 12F1,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 141,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 15B1,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 18C1,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 19A1,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 19F1,2 2,2 micrograms
polysaccharide bacteria (pneumococca) Streptococcus pneumoniae serotype 22F1,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 23F1,2 2,2 micrograms
polysaccharide bacterium (pneumococca) Streptococcus pneumoniae serotype 33F1,2 2,2 micrograms
1Conjugated with CRM197 carrier protein (approximately 51 µg per dose).
2Adsorbed on aluminium phosphate (0.125 mg aluminium per dose).
(2) anti-pneumococcal infections vaccines used in the sequencing scheme:
(2a) A 15-valent polysaccharide conjugate vaccine against pneumococcal infections, which contains:
Streptococci pneumoniae serotypi 11,2 polysaccharide 2,0 micrograms
Streptococci pneumoniae serotypi 31,2 polysaccharide 2,0 micrograms
Streptococci pneumoniae serotypi 41,2 polysaccharide 2,0 micrograms
Streptococci pneumoniae serotypi 51,2 polysaccharide 2,0 micrograms
Streptococci pneumoniae serotypi 6A1,2 polysaccharide 2,0 micrograms
Streptococci pneumoniae serotypi 6B1,2 polysaccharide 4,0 micrograms
Streptococci pneumoniae serotypi 7F1,2 polysaccharide 2,0 micrograms
Streptococci pneumoniae serotypi 9V1,2 polysaccharide 2,0 micrograms
Streptococci pneumoniae serotypi 141,2 polysaccharide 2,0 micrograms
Streptococci pneumoniae serotypi 18C1,2 polysaccharide 2,0 micrograms
Streptococci pneumoniae serotypi 19A1,2 polysaccharide 2,0 micrograms
Streptococci pneumoniae serotypi 19F1,2 polysaccharide 2,0 micrograms
Streptococci pneumoniae serotypi 22F1,2 polysaccharide 2,0 micrograms
Streptococci pneumoniae serotypi 23F1,2 polysaccharide 2,0 micrograms
Streptococci pneumoniae serotypi 33F1,2 polysaccharide 2,0 micrograms
1Conjugated with protein carrier CRM197. CRM197 is a non-toxic mutation of diphtheric toxin (originating in Corynebacterium diphtheriae C7) recombinant expressed in Pseudomonas fluorescens.
2Adsorbed on aluminium phosphate adjuvant.
A
(2b) A 23-valent polysaccharide vaccine against pneumococcal infections, which contains:
25 micrograms of the following 23 pneumococcal polysaccharide serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F.
(3) pneumococcal infections vaccines used in the sequencing scheme:
(3a) A 13-valent polysaccharide conjugate vaccine against pneumococcal infections, which contains:
Streptococci pneumoniae polysaccharide serotype 11 2,2 micrograms
Streptococci pneumoniae polysaccharide serotype 31 2,2 micrograms
Streptococci pneumoniae polysaccharide serotype 41 2,2 micrograms
Streptococci pneumoniae polysaccharide serotype 51 2,2 micrograms
Streptococci pneumoniae polysaccharide serotype 6A1 2,2 micrograms
Streptococci pneumoniae polysaccharide serotype 6B1 4,4 micrograms
Streptococci pneumoniae polysaccharide serotype 7F1 2,2 micrograms
Streptococci pneumoniae polysaccharide serotype 9V1 2,2 micrograms
Streptococci pneumoniae polysaccharide serotype 141 2,2 micrograms
Streptococci pneumoniae polysaccharide serotype 18C1 2,2 micrograms
Streptococci pneumoniae polysaccharide serotype 19A1 2,2 micrograms
Streptococci pneumoniae polysaccharide serotype 19F1 2,2 micrograms
Streptococci pneumoniae polysaccharide serotype 23F1 2,2 micrograms
1Conjugated with CRM197 carrier protein and adsorbed on aluminium phosphate.
A
3b) A 23-valent polysaccharide vaccine against pneumococcal infections, which contains:
25 micrograms of the following 23 pneumococcal polysaccharide serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F.
Communication from the Ministry of Health No 20 / 2018 Coll., on the antigenic composition of the vaccine against pneumococcal infections for vaccination of insured persons over 65 years of age, is deleted.
This communication shall take effect on 1 July 2024.
Minister:
Prof. MUDr. Válek, CSc., MBA, EBIR, v. r.
Sign in for notes, favorites and notifications
Regulation Information
| Citation | Communication from the Ministry of Health No. 118 / 2024 Coll., on the antigenic composition of vaccines against pneumococcal infections for vaccination of insured persons over 65 years of age |
|---|---|
| Regulation Type | Communication |
| Author | - |
| Collection | Code of Laws |
| Date of Promulgation | 14.05.2024 |
|---|---|
| Effective from | - |
| Effective until | - |
| Status | Valid |
The regulation text is for informational purposes only.
Comments 0